Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Clofarabine Significantly Increases Eradication of Minimal Residual Disease of B-Precursor ALL Compared to High-Dose Cytarabine in Randomized Trial Coall 08-09

Gabriele Escherich, MD, Udo Zur Stadt, PhD, Dagmar Dilloo, MD, Joerg Faber, MD PhD, Tobias Feuchtinger, MD, Thomas Imscheiler, MD, Norbert Jorch, MD, Arnulf Pekrun, Irene Schmid, MD, Martin Zimmermann, PhD, Martin A. Horstmann, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-136149

Published: 2020

Journal Articles

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Blood (2019) 134 (Supplement_1): 1351.

https://doi.org/10.1182/blood-2019-126523

Published: 2019

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Methotrexate-Associated Toxicity in Children with Down Syndrome and Acute Lymphoblastic Leukemia during Consolidation Therapy with High Dose Methotrexate According to ALL-BFM Treatment Regimen

Mirko Kroll, Kirsten Bleckmann, MD, Anja Möricke, MD, Denis Martin Schewe, MD, Martin Stanulla, MD PhD, Martin Zimmermann, PhD, Martin Schrappe, MD PhD, Gunnar Cario, MD

Blood (2018) 132 (Supplement 1): 1378.

https://doi.org/10.1182/blood-2018-99-112114

Published: 2018

Journal Articles

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

Blood (2018) 132 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2018-99-118255

Published: 2018

Journal Articles

TIM-3 Expression on CD4 + Bone Marrow T Cells Predicts Relapse of Pediatric B-Precursor Acute Lymphoblastic Leukemia

Franziska Blaeschke, MD, Semjon Willier, MD, Dana Stenger, Mareike Lepenies, Martin A. Horstmann, MD, Gabriele Escherich, Martin Zimmermann, PhD, Theresa Kaeuferle, PhD, Meino Rohlfs, PhD, Irene Schmid, MD, Michael H. Albert, MD, Vera Binder, MD, Christoph Klein, MD PhD, Tobias Feuchtinger, MD

Blood (2018) 132 (Supplement 1): 2833.

https://doi.org/10.1182/blood-2018-99-118376

Published: 2018

Journal Articles

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

Blood (2018) 132 (Supplement 1): 2826.

https://doi.org/10.1182/blood-2018-99-117978

Published: 2018

Journal Articles

Outcome of Children Relapsing after First Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia: A Retrospective I-BFM Analysis of 336 Children between 2005 and 2016

Blood (2017) 130 (Supplement 1): 272.

https://doi.org/10.1182/blood.V130.Suppl_1.272.272

Published: 2017

Journal Articles

PDX Models Recapitulate Genetics and Epigenetics of Pediatric T-Cell Leukemia

Blood (2017) 130 (Supplement 1): 2723.

https://doi.org/10.1182/blood.V130.Suppl_1.2723.2723

Published: 2017

Journal Articles

Relapsing Pediatric T-Cell Acute Lymphoblastic Leukemia Downregulates T-Cell Properties and Upregulates Cell Adhesion

Blood (2017) 130 (Supplement 1): 2726.

https://doi.org/10.1182/blood.V130.Suppl_1.2726.2726

Published: 2017

Journal Articles

The Impact of Sex on Clinical Outcome and Toxicity in Children and Adolescents with Acute Lymphoblastic Leukemia. a Report from the BFM Study Group

Alexander Claviez, MD, Nina Brinkmeier, Martin Stanulla, MD PhD, Martin Zimmermann, PhD, Martin Schrappe, MD PhD, Anja Moericke, MD

Blood (2017) 130 (Supplement 1): 2555.

https://doi.org/10.1182/blood.V130.Suppl_1.2555.2555

Published: 2017

Journal Articles

Daunorubicin during Delayed Intensification Considerably Lowers the Incidence of Infectious Complications but Might Result in Decreased Disease-Free Survival Compared to Adriamycin in Children with Acute Lymphoblastic Leukemia - a Randomized Comparison in Trial Coall 08-09.

Gabriele Escherich, MD, Franziska Schramm, MD, Martin Zimmermann, PhD, Martin A. Horstmann, MD

Blood (2017) 130 (Supplement 1): 2599.

https://doi.org/10.1182/blood.V130.Suppl_1.2599.2599

Published: 2017

Journal Articles

Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000

Laura Hinze, Stefanie V. Junk, PhD, Norman Klein, Anja Moricke, MD, Gunnar Cario, MD, Christian P. Kratz, MD, Richard S Houlston, MD PhD, Claus R Bartam, MD, Rolf Koehler, PhD, Martin Zimmermann, PhD, Martin Schrappe, MD PhD, Martin Stanulla, MD PhD

Blood (2017) 130 (Supplement 1): 3981.

https://doi.org/10.1182/blood.V130.Suppl_1.3981.3981

Published: 2017

Journal Articles

MAP3K7 Is Recurrently Deleted in Pediatric T-Lymphoblastic Leukemia and Affects Cell Proliferation Independently of NF-κB

David M. Cordas dos Santos, Juliane Eilers, Alfonso Vizcaino, Elena Orlova, Martin Zimmermann, PhD, Martin Stanulla, MD PhD, Martin Schrappe, MD PhD, Kathleen Börner, PhD, Dirk Grimm, PhD, Martina Muckenthaler, Andreas E. Kulozik, MD PhD, Joachim B. Kunz, MD

Blood (2017) 130 (Supplement 1): 1447.

https://doi.org/10.1182/blood.V130.Suppl_1.1447.1447

Published: 2017

Journal Articles

Distinct Outcome Based on Fusion Transcript in t(16;21) Rearranged Pediatric AML, a Collaborative Retrospective Analysis By the I-BFM SG

Blood (2017) 130 (Supplement 1): 184.

https://doi.org/10.1182/blood.V130.Suppl_1.184.184

Published: 2017

Journal Articles

AML SCT-BFM 2007: Results of the Prospective Hematopoietic Stem Cell Transplantation (HCT) Trial of the Berlin-Frankfurt-MÃ¼nster (BFM) Study Group for Children with Very High Risk Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 599.

https://doi.org/10.1182/blood.V130.Suppl_1.599.599

Published: 2017

Journal Articles

TP53 , ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia

Stefanie V. Junk, PhD, Norman Klein, Sabine Schreek, Martin Zimmermann, PhD, Anja Möricke, MD, Kirsten Bleckmann, Gunnar Cario, MD, Martin Schrappe, MD PhD, Christian P. Kratz, MD, Martin Stanulla, MD PhD

Blood (2017) 130 (Supplement 1): 884.

https://doi.org/10.1182/blood.V130.Suppl_1.884.884

Published: 2017

Journal Articles

Gemtuzumab in Children with Relapsed and Refractory Acute Myeloid Leukemia Treated on Compassionate-Use Basis: A Report of the AML-BFM Study Group

Mareike Rasche, MD, Beate Lerius, Ursula Creutzig, MD PhD, Martin Zimmermann, PhD, C. Michel Zwaan, MD PhD, Dirk Reinhardt, MD PhD

Blood (2016) 128 (22): 1637.

https://doi.org/10.1182/blood.V128.22.1637.1637

Published: 2016

Journal Articles

Identification of an Ultra High-Risk and Targetable Molecular Signature in Relapsed Pediatric T-ALL

Paulina Richter-Pechanska, PhD, Joachim B. Kunz, MD, Jana Hof, Martin Zimmermann, PhD, Tobias Rausch, PhD, Obul Reddy Bandapalli, PhD, Elena Orlova, Greta Scapinello, Judit Sagi, Martin Stanulla, MD, Martin Schrappe, MD PhD, Renate Kirschner-Schwabe, PhD, Cornelia Eckert, PhD, Vladimir Benes, PhD, Jan O. Korbel, PhD, Martina U. Muckenthaler, PhD, Andreas E Kulozik, MD PhD

Blood (2016) 128 (22): 1084.

https://doi.org/10.1182/blood.V128.22.1084.1084

Published: 2016

Journal Articles

T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial

Stephan Fuhrmann, MD, Leonid Karawajew, Richard Schabath, Anja Moricke, MD, Martin Zimmermann, PhD, Wolf-Dieter Ludwig, Martin Schrappe, MD PhD, Richard Ratei

Blood (2016) 128 (22): 760.

https://doi.org/10.1182/blood.V128.22.760.760

Published: 2016

NARROW

Clofarabine Significantly Increases Eradication of Minimal Residual Disease of B-Precursor ALL Compared to High-Dose Cytarabine in Randomized Trial Coall 08-09

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Methotrexate-Associated Toxicity in Children with Down Syndrome and Acute Lymphoblastic Leukemia during Consolidation Therapy with High Dose Methotrexate According to ALL-BFM Treatment Regimen

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

TIM-3 Expression on CD4 + Bone Marrow T Cells Predicts Relapse of Pediatric B-Precursor Acute Lymphoblastic Leukemia

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

Outcome of Children Relapsing after First Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia: A Retrospective I-BFM Analysis of 336 Children between 2005 and 2016

PDX Models Recapitulate Genetics and Epigenetics of Pediatric T-Cell Leukemia

Relapsing Pediatric T-Cell Acute Lymphoblastic Leukemia Downregulates T-Cell Properties and Upregulates Cell Adhesion

The Impact of Sex on Clinical Outcome and Toxicity in Children and Adolescents with Acute Lymphoblastic Leukemia. a Report from the BFM Study Group

Daunorubicin during Delayed Intensification Considerably Lowers the Incidence of Infectious Complications but Might Result in Decreased Disease-Free Survival Compared to Adriamycin in Children with Acute Lymphoblastic Leukemia - a Randomized Comparison in Trial Coall 08-09.

Genome-Wide Association Study (GWAS) of High-Risk Minimal Residual Disease and Relapse in B-Cell Acute Lymphoblastic Leukemia on Trial AIEOP-BFM ALL 2000

MAP3K7 Is Recurrently Deleted in Pediatric T-Lymphoblastic Leukemia and Affects Cell Proliferation Independently of NF-κB

Distinct Outcome Based on Fusion Transcript in t(16;21) Rearranged Pediatric AML, a Collaborative Retrospective Analysis By the I-BFM SG

AML SCT-BFM 2007: Results of the Prospective Hematopoietic Stem Cell Transplantation (HCT) Trial of the Berlin-Frankfurt-MÃ¼nster (BFM) Study Group for Children with Very High Risk Acute Myeloid Leukemia

TP53 , ETV6 and RUNX1 Germline Variants in Patients Developing Secondary Neoplasms after Treatment for Childhood Acute Lymphoblastic Leukemia

Gemtuzumab in Children with Relapsed and Refractory Acute Myeloid Leukemia Treated on Compassionate-Use Basis: A Report of the AML-BFM Study Group

Identification of an Ultra High-Risk and Targetable Molecular Signature in Relapsed Pediatric T-ALL

T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only